PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs RHHBY |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.7 | 149.5% | — |
| AZN | AstraZeneca PLC | 0.21 | 12.7 | 61.0% | — |
| NVS | Novartis AG | 1.53 | 23.6 | 15.4% | — |
| MRK | Merck & Co., Inc. | 1.73 | 36.7 | 21.2% | — |
| BMY | Bristol-Myers Squibb Company | 2.75 | 14.4 | 5.2% | — |